CoronaryAtlas logo
CoronaryAtlas
LDL cholesterol
Pathway / Lipid retention & oxidation

LDL cholesterol

lipoprotein

LDL accumulation in the arterial intima is the initiating substrate of atherosclerotic plaque formation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleAnchor molecule; ApoB-lipoprotein retention in intima initiates atherosclerosis.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
67
C — non-Type-I
48
A — assay feasibility
84
E — evidence strength
82
T1DI (composite)
41
Specificity differential (R−C)+18.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 1
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduraln/a
4bstent thrombosismag 1
4cin-stent restenosismag 1
5CABG-relatedmag 1
Coverage: 9/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 12 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma (fasting preferred)
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Direct enzymatic (homogeneous) or calculated (Friedewald/Martin)
Reagent / substrate
Cholesterol esterase + cholesterol oxidase + peroxidase, Trinder chromogen; selective detergents for LDL
Platform
Automated chemistry analyzer
Turnaround · availability
Routine · Universal

Literature evidence(60)

Showing 40 of 60 linked references.

Clinical trials(6)